Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Thursday reported a net loss for the first quarter of 2026. Revenues increased 12.2% on a year-over-year basis.
Net sales for the first quarter increased 12.2% year-over-year to $75.7 million; Med Tech sales grew 26% to $35.3 millionAt $40.4 million, Med Device sales were up 2.3% in Q1, compared to $39.5 million in the prior-year periodThe company recorded a net loss of $10.9 million or $0.26 per share for Q1, vs. a loss of $12.8 million or $0.31 per share last yearExcluding special items, adjusted net loss was $4.2 million or $0.10 per share, compared to $4.4 million or $0.11 per share in Q1 2025Adjusted EBITDA, excluding one-off items, was $2.2 million, compared to a loss of $0.2 million in the first quarter of 2025The management said it continues to expect to be cash flow positive for the full fiscal year 2026The company raised its FY26 net sales guidance to $308-313 million from the earlier outlook of $305-310 millionIt now expects a loss per share in the range of $0.33 to $0.23 for FY26, compared to the previous forecast for a loss per share between $0.35 and $0.25
